GlassScriptPhysician profile
Bryant Nguyen
NPI 1902085426
$13,299.34
in general payments reported to CMS, 2019-2025
49 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,969 · 2020: $499 · 2021: $4,810 · 2022: $916 · 2023: $1,439 · 2024: $872 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,105.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,250.00 | 2021 | |
| La Jolla Pharmaceutical Company | $1,841.18 | 2019 | |
| Abiomed | $841.22 | 2019-2025 | Impella |
| Medtronic, INC. | $686.22 | 2021-2024 | Corevalve Evolut R, Melody Tpv, Onyx Frontier |
| Amgen INC. | $681.54 | 2019-2025 | Repatha, Repatha, Otezla |
| Biotronik INC. | $610.17 | 2019-2024 | Biomonitor, Amvia Edge |
| Novartis Pharmaceuticals Corporation | $601.38 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $450.13 | 2019-2025 | Brilinta, Lokelma, Farxiga |
| Abbott Laboratories | $422.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $382.49 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $380.42 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $287.27 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.25 | 2021-2025 | Jardiance, Ofev |
| Medtronic Vascular, INC. | $270.81 | 2019-2020 | |
| Pfizer INC. | $236.04 | 2019-2025 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.